The FDA may be hesitant to insist on another trial considering the EMA have judged it as not required. EMA approval would mean share price in the hundreds of dollars. If the drug is selling in EMA area (and potentially UK/AUS) and not USA this will put pressure on FDA.
Market Data 
Markets 
AI
